Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment

Jacob Wackerhausen/iStock via Getty Images Therefore, it could end up being that this recombinant protein from Biohaven could have a synergistic effect with current treatment options. This is possible because of the mechanism of action of this drug compared to the other approved ones. In essence, taldefgrobep alfa is a myostatin inhibitor and its goal is to knock down the signaling of myostatin itself. This is important, because overactive myostatin activation inhibits muscle growth. Thus, the mechanism of ...